Home » Newsletters » BioWorld Science

BioWorld Science

May 16, 2008

View Archived Issues

Novel antiinflammatory agents disclosed in recent patents

Health Canada approves PolyMedix's CTA for phase I clinical study of PMX-30063

Medtronic initiates phase III trial comparing Endeavor with Xience coronary stents

Alseres announces 12-month interim data from phase I/IIa clinical trial of Cethrin in SCI

Nventa reports positive results from third cohort in phase I clinical trial of HspE7 for CIN

arGentis licenses ARG-103 for dry eye syndrome from Southern College of Optometry

Ranbaxy and Merck & Co. sign collaboration agreement for antiinfective drug candidates

Health Canada grants approval to Thallion to initiate phase II clinical trial of TLN-4601

Placental growth factor blockade useful in mouse models of CNV

Novel VEGFR-2 inhibitor profiled at Bristol-Myers Squibb

New therapeutic agents for cancer reported in recent patent literature

Bristol-Myers and KAI enter license agreement for KAI-9803 in cardiovascular disease

Valeant reports positive results from phase III RESTORE 2 trial of retigabine in epilepsy

ImClone initiates enrollment in phase II clinical trial of IMC-A12 in liver cancer

Synvista initiates dosing in a phase II study of alagebrium in diastolic heart failure

Oncolytics receives U.K. approval to initiate phase II clinical trial of Reolysin in cancer

AEterna Zentaris initiates dosing in phase III safety trial of cetrorelix in BPH

Ardana reports preliminary results from phase III study of testosterone cream in hypogonadal men

Chugai and Taisho sign agreement to codevelop and comarket eldecalcitol for osteoporosis

Newron acquires Hunter-Fleming

Pfizers's ziprasidone under study in children and adolescents with bipolar I disorder

Novel DNA vaccine encoding calreticulin shows protection against anthrax toxin in vivo

Allos Therapeutics reports interim response and safety data from phase II trial

Orexo submits NDA to the FDA for Sublinox (OX-22) for short-term insomnia

Positive preclinical and clinical results of ViroChem's novel HCV polymerase inhibitor

Wyeth's Pristiq available in U.S. pharmacies for major depressive disorder

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...